684 patents
Page 7 of 35
Utility
Mammalian Cell Culture
27 Apr 23
The invention provides a method for culturing mammalian cells.
Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
Filed: 20 Dec 22
Utility
Diagnostic Antibodies Against Mucin 17 and Uses Thereof
27 Apr 23
The present invention relates to antibodies that bind to human and monkey mucin 17 (MUC17).
Kurt Edelmann, Julie Bailis
Filed: 19 Mar 21
Utility
Aryl Sulfonyl Compounds as CCR6 Inhibitors
27 Apr 23
Penglie ZHANG, Daniel R. MARSHALL, Howard S. ROTH, Aubrie HARLAND
Filed: 17 Aug 22
Utility
Systems and Approaches for Sterilizing a Drug Delivery Device
27 Apr 23
An on-body injector system includes a drug container assembly including a container, a seal member, and a sealing interface between the seal member and the container.
Loic Barbedette, Shaun Devitt, Wael Mismar
Filed: 21 Dec 22
Utility
Aqueous Formulation of Erythropoiesis Stimulating Protein Stabilised by Antioxidants for Parenteral Administration
27 Apr 23
The present invention relates to stable aqueous protein formulations.
Christopher James Sloey, Jason Ko, Tiansheng Li
Filed: 1 Sep 22
Utility
Mammalian Cell Culture
20 Apr 23
The invention provides a method for culturing mammalian cells.
Brian D. FOLLSTAD, Rebecca E. McCOY, Arvia E. MORRIS
Filed: 14 Dec 22
Utility
Immunomodulator Compounds
20 Apr 23
Christopher LANGE, Viengkham MALATHONG, Darren J. McMURTRIE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
Filed: 13 Jun 22
Utility
Methylation of MCL-1 Compounds
20 Apr 23
Disclosed herein is an improved process for the synthesis of compound (A): (A), or a salt or solvate thereof via methylation of compound (B): (B), or a salt or solvate thereof, a crystalline hydrate of compound A, and pharmaceutical formulations comprising a crystalline hydrate of compound (A).
Michal ACHMATOWICZ, Sheng CUI, Tsang-Lin HWANG, Neil Fred LANGILLE, Janine K. TOM, James E. HUCKLE, Markian STEC, Tian WU, Sean P. BROWN
Filed: 30 Mar 21
Utility
Combination Therapy Including a Kras G12C Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers
20 Apr 23
James Russell LIPFORD, Jude Robert CANON, Anne Y. SAIKI, Karen Louise REX
Filed: 21 Jul 22
Utility
Chimeric Receptors to FLT3 and Methods of Use Thereof
20 Apr 23
Antigen binding molecules, chimeric receptors, and engineered immune cells to FLT3 are disclosed in accordance with the invention.
Alice BAKKER, Lawren WU, Tara ARVEDSON, Jed J. WILTZIUS, Ruben Alvarez RODRIGUEZ
Filed: 23 May 22
Utility
2-OXINDOLE Compounds
20 Apr 23
Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.
Xi CHEN, Dean R. DRAGOLI, Pingchen FAN, Manmohan Reddy LELETI, Rebecca M. LUI, Viengkham MALATHONG, Jay P. POWERS, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
Filed: 1 Aug 22
Utility
Drug Delivery Device with Messaging Label
20 Apr 23
A drug delivery device includes a housing, a reservoir, a cannula, one or more light sources, a label, and a controller.
Brian Stonecipher
Filed: 21 Dec 22
Utility
DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS
13 Apr 23
Pingchen FAN, Christopher W. LANGE, Viengkham MALATHONG, Venkat Reddy MALI, Sreenivas PUNNA, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
Filed: 13 Sep 22
Utility
Pharmaceutical Composition Comprising Bispecific Antibody Constructs
6 Apr 23
The present invention provides novel and stable pharmaceutical compositions comprising bispecific single chain antibody constructs, cyclodextrins and a buffer.
Sekhar Kanapuram, Ramil Latypov, Balakumar Thangaraj, Cornelius Pompe
Filed: 30 Jun 22
Utility
Salts and Crystal Forms of Omecamtiv Mecarbil
6 Apr 23
Provided herein are free base crystalline forms, crystalline salts, and an amorphous salts of omecamtiv mecarbil.
Henry Morrison, Sheng Cui, Kyle Quasdorf, Evelyn Yanez, Bin Peter Quan, Ron C. Kelly, Sebastien Caille, Lingyun Xiao, David Pearson, Jaclyn Raeburn, Alisa Golightly, Bradley Morgan, Matthew Peterson, Alex Eberlin, Alexander Oblezov
Filed: 2 Sep 22
Utility
Impact Testing Apparatuses and Methods for Drug Delivery Devices
6 Apr 23
Impact testing apparatuses are disclosed which simulate and measure various impact-related events associated with the operation of a drug delivery device.
Julian Jazayeri, Sean Fitzgibbon, Joshua Tamsky, Christopher R. Folk
Filed: 30 Nov 22
Utility
C5aR INHIBITOR REDUCTION OF URINARY sCD163
6 Apr 23
Provided herein are methods of treating ANCA-associated vasculitis (AAV) in individuals in need thereof comprising administering a complement component 5a receptor (C5aR) antagonist.
Jun DENG, Thomas J. SCHALL, Petrus BEKKER
Filed: 29 Jul 22
Utility
C5AR Antagonists
30 Mar 23
Compounds are provided that are modulators of the C5a receptor.
Pingchen FAN, Kevin Lloyd GREENMAN, Manmohan Reddy LELETI, Yandong LI, Jay POWERS, Hiroko TANAKA, Ju YANG, Yibin ZENG
Filed: 26 Sep 22
Utility
Combination Therapy Using C-C Chemokine Receptor 4 (CCR4) Antagonists and One or More Immune Checkpoint Inhibitors
30 Mar 23
The present disclosure is drawn to the combination therapy of a C—C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.
Shijie LI, Venkat Reddy MALI, Rajinder SINGH, Ju YANG, Penglie ZHANG
Filed: 16 Aug 22
Utility
Devices and Methods for Assisting a User of a Drug Delivery Device
30 Mar 23
Devices and methods are disclosed for assisting a user of a drug delivery device with an application executing on a mobile computing device.
Adam B. McCullough, Basel Hasan Taha, Jimmie L. Ward, Steven William Badelt, Ferry Tamtoro, Huaying Yang, Mark Ka Lai Lee, Desheng Yin, Scott R. Gibson, Donald Busby, Peter V. Shultz, Keith P. Kogler
Filed: 8 Sep 22